# An Open-label Study of GC012F in Rheumatoid Arthritis.

> **NCT07315503** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 9 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** LD and GC012F CAR-T Cell Injection
- **DRUG:** GC012F CAR-T Cell Injection

## Key facts

- **NCT ID:** NCT07315503
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-01-15
- **Final completion:** 2041-01-15
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315503, "An Open-label Study of GC012F in Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07315503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*